Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects
A. Eiken, A. L. Smith, S. A. Skupa, E. Schmitz, S. Rana, S. Singh, S. Kumar, J. R. Mallareddy, A. A. de Cubas, A. Krishna, A. Kalluchi, J. Rowley, C. R. D'Angelo, M. A. Lunning, R. G. Bociek, , D. ElGamal
This paper evaluates SpiD3, a novel spirocyclic dimer, showing potent anti-leukemic effects in CLL cells, including resistance to ibrutinib, by targeting NF-κB signaling and the UPR.
bioRxiv · Jan 31, 2024Cancer Biology